Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharm company Nymox Pharmaceutical has received results from the third interim safety analysis of its ongoing mid-stage trial of NX-1207, its investigational treatment for benign prostatic hyperplasia, that show the drug is not associated with any serious side effects.
Subscribe to our email newsletter
NX-1207 is Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH). The company believes the drug shows good promise as a potential first-line treatment for BPH.
In two previously completed trials, subjects treated with NX-1207 showed statistically significant overall mean symptom improvement and shrinkage in prostate size. There were no serious adverse events from the drug in these trials. Subjects that were followed for up to two years post-treatment showed even further statistically significant symptom improvement. The analysis of the present on-going phase II trial confirms the drug’s safety in this patient population.
According to Nymox, BPH afflicts approximately half of all men over the age of 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.